Price
Financials
Consolidated, Rs crore| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 35 | 67 | 56 | 87 | 81 | 66 | 99 |
| Expenses | 33 | 63 | 53 | 82 | 78 | 65 | 97 |
| Operating Profit | 2 | 4 | 2 | 5 | 3 | 2 | 2 |
| OPM % | 6% | 6% | 4.4% | 5% | 3.6% | 2.7% | 2.2% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 2 | 1 | 3 | 1 | 0 | 0 |
| Tax % | 39% | 20% | 33% | 27% | 37% | 83% | 29% |
| Net Profit | 1 | 2 | 1 | 2 | 1 | 0 | 0 |
| EPS in Rs | 0.52 | 1.06 | 0.33 | 1.30 | 0.46 | 0.01 | 0.19 |
| Mar 2023 6m | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales | 33 | 122 | 168 | 166 |
| Expenses | 31 | 116 | 161 | 161 |
| Operating Profit | 2 | 6 | 8 | 5 |
| OPM % | 7% | 5% | 4.5% | 2.7% |
| Other Income | 0 | 0 | 1 | 0 |
| Interest | 1 | 3 | 4 | 3 |
| Depreciation | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 3 | 4 | 1 |
| Tax % | 29% | 24% | 30% | 32% |
| Net Profit | 1 | 2 | 3 | 1 |
| EPS in Rs | 0.76 | 1.38 | 1.75 | 0.41 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | 71% | -2% | ||
| Compounded Profit Growth | % | % | -8% | -76% | ||
| Stock Price CAGR | % | % | -35% | -59% | ||
| Return on Equity | % | % | 8% | 2% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 12 | 18 | 18 | 18 |
| Reserves | 1 | 10 | 14 | 14 |
| Borrowings | 40 | 41 | 54 | 56 |
| Other Liabilities | 9 | 12 | 25 | 34 |
| Total Liabilities | 63 | 81 | 110 | 122 |
| Fixed Assets | 1 | 1 | 1 | 1 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 | 0 |
| Other Assets | 61 | 80 | 109 | 121 |
| Total Assets | 63 | 81 | 110 | 122 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity | -40 | -9 | -4 | 3 |
| Cash from Investing Activity | -1 | 0 | -0 | -0 |
| Cash from Financing Activity | 41 | 8 | 5 | -2 |
| Net Cash Flow | 0 | -0 | 0 | 0 |
| Free Cash Flow | -40 | -9 | -5 | 3 |
| CFO/OP | -1,765% | -127% | -38% | 68% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 241 | 94 | 91 | 165 |
| Inventory Days | 408 | 139 | 133 | 99 |
| Days Payable | 87 | 32 | 45 | 68 |
| Cash Conversion Cycle | 563 | 202 | 179 | 196 |
| Working Capital Days | 299 | 131 | 120 | 126 |
| ROCE % | 10% | 11% | 5% |
| Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Promoters | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% | 56.72% |
| Public | 43.28% | 43.27% | 43.28% | 43.28% | 43.28% | 43.28% |
| No. of Shareholders | 621 | 528 | 418 | 463 | 478 | 514 |
Fundamentals
Market Cap₹ 15.9 Cr.
Current Price₹ 9.00
Stock P/E21.8
Book Value₹ 17.9
ROCE5.10 %
ROE2.33 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-2%
Compounded Profit Growth (TTM)-76%
Consolidated figures.
Ownership
Promoter holding56.72% (+0.00 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | MONOPHARMA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +3.6% | -2.8% | +6.4 pts |
| 1 month | +4.3% | -6.8% | +11.1 pts |
| 3 months | -30.2% | -7.6% | -22.6 pts |
| 6 months | -46.6% | +0.4% | -47.0 pts |
| 1 year | -64.7% | -9.9% | -54.8 pts |
| 2 years | -83.0% | -13.6% | -69.5 pts |
| 3 years | -74.0% | +14.2% | -88.2 pts |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Mar 2026Sales ₹99 Cr +76.8% vs Mar 2024.
Net profit ₹0 Cr.
Against our estimate for Mar 2026: sales +10.9%, profit -100.0% miss.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
No corporate actions on record.
No announcements in our files yet.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
High low price variation greater than 150perc in previous 12 monthsHigh low price variation greater than 200perc in previous 365 DaysLess than 100 unique PAN traded in previous 30 daysMandatory Market making period in SME scrip is overSME scrip is not regularly traded
Quick answers
What is the market cap of Mono Pharmacare Ltd?
Mono Pharmacare Ltd (MONOPHARMA) has a market capitalisation of Rs 15.9 Cr. at the 2026-09-30 close.
What is the P/E ratio of Mono Pharmacare Ltd?
Mono Pharmacare Ltd trades at a P/E of 21.8 on trailing twelve-month profit, at the 2026-09-30 close.
What were Mono Pharmacare Ltd's latest quarterly results?
In the Mar 2026 quarter, Mono Pharmacare Ltd sales was Rs 99 Cr (+76.8% vs Mar 2024) and net profit was Rs 0 Cr.
What is the 52-week high and low of Mono Pharmacare Ltd?
The 52-week high is Rs 24.00 and the 52-week low is Rs 7.50.